Sandbox:haytham1: Difference between revisions
Jump to navigation
Jump to search
| Line 34: | Line 34: | ||
===Immunochemotherapeutic regimens for management of patients without chromosome 17p deletion or chromosome 11q deletion=== | ===Immunochemotherapeutic regimens for management of patients without chromosome 17p deletion or chromosome 11q deletion=== | ||
Bendamustine + Rituximab | Bendamustine + Rituximab | ||
Chlorambucil | Chlorambucil | ||
Chlorambucil + PredniSONE | Chlorambucil + PredniSONE | ||
Cladribine | Cladribine | ||
Cyclophosphamide/PredniSONE | Cyclophosphamide/PredniSONE | ||
Cyclophosphamide/PredniSONE + Rituximab | Cyclophosphamide/PredniSONE + Rituximab | ||
FCR (Fludarabine/Cyclophosphamide + Rituximab) | FCR (Fludarabine/Cyclophosphamide + Rituximab) | ||
Fludarabine | Fludarabine | ||
FR (Fludarabine + Rituximab) | FR (Fludarabine + Rituximab) | ||
MethylPREDNISolone (Pulse) | MethylPREDNISolone (Pulse) | ||
PCR (Pentostatin/Cyclophosphamide + Rituximab) | PCR (Pentostatin/Cyclophosphamide + Rituximab) | ||
Rituximab | Rituximab | ||
===Immunochemotherapeutic regimens for management of patients with chromosome 17p deletion=== | ===Immunochemotherapeutic regimens for management of patients with chromosome 17p deletion=== | ||
Alemtuzumab + Rituximab | Alemtuzumab + Rituximab | ||
Bendamustine + Rituximab | Bendamustine + Rituximab | ||
FCR (Fludarabine/Cyclophosphamide + Rituximab) | FCR (Fludarabine/Cyclophosphamide + Rituximab) | ||
FR (Fludarabine + Rituximab) | FR (Fludarabine + Rituximab) | ||
HDMP (High-Dose Methylprednisolone) + Rituximab | HDMP (High-Dose Methylprednisolone) + Rituximab | ||
===Immunochemotherapeutic regimens for management of patients with chromosome 11q deletion=== | ===Immunochemotherapeutic regimens for management of patients with chromosome 11q deletion=== | ||
Bendamustine + Rituximab | Bendamustine + Rituximab | ||
Chlorambucil | Chlorambucil | ||
Chlorambucil + PredniSONE | Chlorambucil + PredniSONE | ||
Cyclophosphamide/PredniSONE | Cyclophosphamide/PredniSONE | ||
Cyclophosphamide/PredniSONE + Rituximab | Cyclophosphamide/PredniSONE + Rituximab | ||
FCR (Fludarabine/Cyclophosphamide + Rituximab) | FCR (Fludarabine/Cyclophosphamide + Rituximab) | ||
PCR (Pentostatin/Cyclophosphamide + Rituximab) | PCR (Pentostatin/Cyclophosphamide + Rituximab) | ||
Reduced-dose FCR (Fludarabine/Cyclophosphamide + Rituximab) | Reduced-dose FCR (Fludarabine/Cyclophosphamide + Rituximab) | ||
Rituximab | Rituximab | ||
Revision as of 16:14, 16 October 2015
Initial patients evaluation | |||||||||||||||||||||||||||||||||||||||||||||||||
History Physical examination Complete blood count | |||||||||||||||||||||||||||||||||||||||||||||||||
Staging | |||||||||||||||||||||||||||||||||||||||||||||||||
Rai Staging System Binet Staging System | |||||||||||||||||||||||||||||||||||||||||||||||||
Rai stage 3-4 Binet stage B-C | Rai stage 0-2 Binet stage A | ||||||||||||||||||||||||||||||||||||||||||||||||
Evaluate patients by cumulative index illness rating scale | Patients managed by observation and close follow-up | ||||||||||||||||||||||||||||||||||||||||||||||||
Frail patients (CIRS ≥6) | Fit patients (CIRS <6) | ||||||||||||||||||||||||||||||||||||||||||||||||
Retixumab/obinutuzumab AND chlorambucil | FISH chromosomal analysis | ||||||||||||||||||||||||||||||||||||||||||||||||
Immunochemotherapeutic regimens for management of patients without chromosome 17p deletion or chromosome 11q deletion here | Immunochemotherapeutic regimens for management of patients with chromosome 17p deletion | Immunochemotherapeutic regimens for management of patients with chromosome 11q deletion | |||||||||||||||||||||||||||||||||||||||||||||||
Patients Age | |||||||||||||||||||||||||||||||||||||||||||||||||
Age <70 years | Age ≥70 years | ||||||||||||||||||||||||||||||||||||||||||||||||
chemotherapy
Immunochemotherapeutic regimens for management of patients without chromosome 17p deletion or chromosome 11q deletion
Bendamustine + Rituximab
Chlorambucil
Chlorambucil + PredniSONE
Cladribine
Cyclophosphamide/PredniSONE
Cyclophosphamide/PredniSONE + Rituximab
FCR (Fludarabine/Cyclophosphamide + Rituximab)
Fludarabine
FR (Fludarabine + Rituximab)
MethylPREDNISolone (Pulse)
PCR (Pentostatin/Cyclophosphamide + Rituximab)
Rituximab
Immunochemotherapeutic regimens for management of patients with chromosome 17p deletion
Alemtuzumab + Rituximab
Bendamustine + Rituximab
FCR (Fludarabine/Cyclophosphamide + Rituximab)
FR (Fludarabine + Rituximab)
HDMP (High-Dose Methylprednisolone) + Rituximab
Immunochemotherapeutic regimens for management of patients with chromosome 11q deletion
Bendamustine + Rituximab
Chlorambucil
Chlorambucil + PredniSONE
Cyclophosphamide/PredniSONE
Cyclophosphamide/PredniSONE + Rituximab
FCR (Fludarabine/Cyclophosphamide + Rituximab)
PCR (Pentostatin/Cyclophosphamide + Rituximab)
Reduced-dose FCR (Fludarabine/Cyclophosphamide + Rituximab)
Rituximab